296:. So the vinca alkaloids do much more damage to the lymphoid cell lines (including the T-cell lines responsible for antileukemic immunity) than to the myeloid cell lines. Moreover, vinca alkaloids in the context of AML cause AML cells to undergo a cell cycle arrest in the phase that renders those cells less sensitive to cytarabine and anthracyclines.
289:) to the "7+3" regimen, which addition was quite popular in AML(ALL?) in old times (when the biology of AML and the differences between AML and ALL was poorly understood) proved to be harmful in AML, lowering the chance of the patient to get remission. This is because vinca alkaloids are rapidly deactivated in myeloid cells by their
274:
There were attempts to intensify the "7+3" regimen in order to try to improve its efficacy. Attempts were made to prolong the course (cytarabine for 10 days instead of 7, or daunorubicin/idarubicin for 4–5 days instead of 3).
334:(or DAE = DA + etoposide) induction regimen in AML. The ADE induction (unlike, say, combinations of 7+3 with vinca alkaloids or prednisolone) is still sometimes used, especially in poor-risk AML patients.
278:
On the other hand, there were attempts to minimize the toxicity of the regimen by reducing the dose or the duration of the course. But this proved to compromise the efficacy of the regimen.
398:
381:
Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study
370:
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
330:
of benefit in poor-risk patients (many of which are primary refractory to standard "7+3" induction regimens). It gave rise to the so-called
17:
51:
369:
65:
The name "7+3" comes from the duration of chemotherapy course, which consists of 7 days of standard-dose
47:
55:
43:
39:
8:
380:
350:
342:
331:
214:
104:
62:
and requires less chemotherapy (if requires it at all, which is not always the case).
42:
that is most often used today (as of 2014) as first-line induction therapy (to induce
159:
346:
312:
59:
293:
77:
300:
392:
338:
70:
308:
304:
252:
142:
93:
81:
31:
286:
282:
85:
236:
197:
181:
126:
89:
73:
66:
323:
316:
215:
Standard-dose cytarabine plus mitoxantrone (MA or MAC chemotherapy)
105:
Standard-dose cytarabine plus daunorubicin (DA or DAC chemotherapy)
160:
Standard-dose cytarabine plus idarubicin (IA or IAC chemotherapy)
35:
290:
319:) to the "7+3" regimen is also of no benefit in AML.
399:
Chemotherapy regimens used in acute myeloid leukemia
27:
Acute myelogenous leukemia induction therapy regimen
390:
269:
14:
391:
244:IV continuous infusion over 24 hours
189:IV continuous infusion over 24 hours
134:IV continuous infusion over 24 hours
54:form, which is better treated with
24:
25:
410:
326:to the standard "7+3" regimen is
281:The addition of vinca alkaloids (
99:
374:
363:
13:
1:
356:
345:regimen, and the addition of
52:acute promyelocytic leukemia
7:
10:
415:
311:or alkylating drugs (like
48:acute myelogenous leukemia
84:(can be substituted for
30:"7+3" in the context of
270:Intensified versions
147:(45) 60–90 mg/m
40:chemotherapy regimen
69:, and 3 days of an
349:gave rise to the
341:gave rise to the
267:
266:
241:100–200 mg/m
212:
211:
186:100–200 mg/m
157:
156:
131:100–200 mg/m
18:DA (chemotherapy)
16:(Redirected from
406:
383:
378:
372:
367:
347:6-mercaptopurine
337:The addition of
322:The addition of
313:cyclophosphamide
263:Days 1, 3 and 5
219:
218:
164:
163:
109:
108:
60:arsenic trioxide
50:, excluding the
21:
414:
413:
409:
408:
407:
405:
404:
403:
389:
388:
387:
386:
379:
375:
368:
364:
359:
301:glucocorticoids
294:myeloperoxidase
272:
217:
162:
107:
102:
78:anthracenedione
28:
23:
22:
15:
12:
11:
5:
412:
402:
401:
385:
384:
373:
361:
360:
358:
355:
271:
268:
265:
264:
261:
258:
255:
249:
248:
245:
242:
239:
233:
232:
229:
226:
223:
216:
213:
210:
209:
206:
203:
200:
194:
193:
190:
187:
184:
178:
177:
174:
171:
168:
161:
158:
155:
154:
151:
148:
145:
139:
138:
135:
132:
129:
123:
122:
119:
116:
113:
106:
103:
101:
100:Dosing regimen
98:
26:
9:
6:
4:
3:
2:
411:
400:
397:
396:
394:
382:
377:
371:
366:
362:
354:
352:
348:
344:
340:
339:6-thioguanine
335:
333:
329:
325:
320:
318:
314:
310:
306:
302:
297:
295:
292:
288:
284:
279:
276:
262:
259:
256:
254:
251:
250:
246:
243:
240:
238:
235:
234:
230:
227:
224:
221:
220:
207:
204:
201:
199:
196:
195:
191:
188:
185:
183:
180:
179:
175:
172:
169:
166:
165:
152:
149:
146:
144:
141:
140:
136:
133:
130:
128:
125:
124:
120:
117:
114:
111:
110:
97:
95:
91:
87:
83:
80:, most often
79:
75:
72:
71:anthracycline
68:
63:
61:
57:
53:
49:
45:
41:
37:
33:
19:
376:
365:
336:
327:
321:
309:methotrexate
305:prednisolone
299:Addition of
298:
280:
277:
273:
253:Mitoxantrone
202:12 mg/m
143:Daunorubicin
94:mitoxantrone
82:daunorubicin
64:
32:chemotherapy
29:
287:vinblastine
283:vincristine
260:IV infusion
257:7 mg/m
86:doxorubicin
357:References
237:Cytarabine
198:Idarubicin
182:Cytarabine
127:Cytarabine
90:idarubicin
74:antibiotic
67:cytarabine
353:regimen.
328:sometimes
324:etoposide
317:melphalan
247:Days 1-7
208:Days 1-3
192:Days 1-7
153:Days 1-3
137:Days 1-7
44:remission
393:Category
205:IV bolus
150:IV bolus
58:and/or
36:acronym
303:(like
291:enzyme
76:or an
38:for a
34:is an
307:) or
231:Days
176:Days
121:Days
46:) in
228:Mode
225:Dose
222:Drug
173:Mode
170:Dose
167:Drug
118:Mode
115:Dose
112:Drug
56:ATRA
351:DAM
343:DAT
332:ADE
315:or
285:or
96:).
92:or
88:or
395::
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.